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Introduction: Zonisamide is one of the most promising antiepileptic drugs that was first 
approved in Europe as add-on therapy in adult patients with partial seizures and recently approved 
as monotherapy. More recently, zonisamide has been approved for pediatric use in the UK and can 
now be prescribed for partial epilepsy in adolescents and children aged 6 years and above.
Aim: This paper systematically reviews the current evidence on the efficacy and tolerability 
of zonisamide as monotherapy and adjunctive therapy for pediatric partial epilepsy.
Methods: Relevant randomized clinical trials and open-label studies were identified by a 
structured PubMed search, supplemented by an additional hand search of reference lists 
and authors’ files.
Results: PubMed database search yielded 12 (four double-blind randomized, eight   open-label) 
clinical trials published over the last 10 years (January 2004 to September 2014) and the pooled 
analysis included a total of 1,555 patients treated with zonisamide.
Conclusion: Zonisamide currently represents a robust option in the treatment of children 
with partial epilepsy, based on its multiple mechanism of action and efficacy in different 
situations.
Keywords: children, clinical trial, partial seizures, tolerability
Introduction
Zonisamide is a benzisoxazole derivative chemically unrelated to other anticonvul-
sant agents. It shows a broad spectrum of mechanistic actions that, in part, overlap 
the actions of phenytoin, carbamazepine, and valproate.1 These include reduction 
of sustained high-frequency repetitive firing of sodium-dependent action potentials, 
inhibition of low-threshold T-type calcium currents, a modulatory effect on GABA-
mediated neuronal inhibition, inhibition of glutamate release, and weak inhibition 
of carbonic anhydrase. The latter may contribute to some of the side effects of this 
drug. Zonisamide also alters the metabolism of dopamine, 5-hydroxytryptamine, and 
acetylcholine.2,3 There is also evidence from in vitro studies that zonisamide may have 
neuroprotective properties.4
Zonisamide is completely absorbed, with a bioavailability of 100% and reaching 
maximum plasma concentration in 2–5 hours of oral ingestion of a dose of 200–400 
mg. This rate of absorption is slightly slower with food intake. Zonisamide is primar-
ily excreted through the urinary tract, with a half-life of 63–69 hours. The half-life 
is decreased with coadministration of other isoenzyme-inducing antiepileptic drugs 
(AEDs), such as phenytoin, phenobarbital, carbamazepine, and sodium valproate, but 
still remains above 24 hours.2 Zonisamide is metabolized by the action of isoenzyme Pediatric Health, Medicine and Therapeutics 2014:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
156
vari and Striano
3A4 in the liver, via the cytochrome P450 pathway. Since this 
process may be affected by other AEDs if used concomitantly, 
zonisamide dose adjustment may be required when used as an 
adjunctive treatment.5 In particular, zonisamide metabolism 
is affected by other AEDs, namely, hepatic enzyme inducers 
such as phenytoin and carbamazepine, which significantly 
reduce zonisamide serum levels.6–8
Zonisamide is a viable first-line and adjunctive therapy 
for a wide range of seizures. In particular, ZNS may be effec-
tive in generalized forms of epilepsies, featuring myoclonic 
and/or absence seizures, such as in patients with juvenile 
myoclonic epilepsy and progressive myoclonic epilepsy, 
although studies of these included a heterogeneous group 
of patients.9–11
Zonisamide is indicated in the EU as monotherapy in 
the treatment of partial seizures with or without secondary 
generalization in adults with newly diagnosed epilepsy, 
and as adjunctive therapy to other AEDs in the treatment 
of adults with partial seizures with or without second-
ary   generalization.12 More recently, zonisamide has been 
approved for pediatric use in the UK and can now be pre-
scribed for partial epilepsy in adolescents and children aged 
6 years and above.13–16 Phase II studies in pediatric patients 
indicate that adjunctive zonisamide has an acceptable safety 
profile in this population and a pharmacokinetic profile 
similar to that observed in adult patients.17 However, there 
is a need for studies to determine the safety, efficacy, and 
tolerability of newer AEDs, such as zonisamide, in children 
of varying ages.
This paper systematically reviews the current evidence on 
the efficacy and tolerability of zonisamide as monotherapy 
and adjunctive therapy for the treatment of pediatric partial 
epilepsy.
Methods
Relevant randomized clinical trials and open-label studies 
in add-on or monotherapy including pediatric patients were 
identified by a structured PubMed search, supplemented 
by an additional hand search of reference lists and authors’ 
(MSV , PS) files. Keywords for the database search included 
“epilepsy”, “pediatric”, “zonisamide”, “clinical trial”, 
“placebo-controlled”, “open-label”, and “therapy”.
Results
PubMed database search yielded 12 (four double-blind 
randomized, eight open-label) clinical trials published over 
the last 10 years (January 2004 to September 2014) and the 
pooled analysis included a total of 1,555 patients treated 
with zonisamide (Table 1). In the large majority of studies, 
zonisamide was administered in patients with drug-resistant 
epilepsy, refractory to at least two AEDs.
Zonisamide as adjunctive therapy
The efficacy of zonisamide as add-on treatment in 
  drug-resistant pediatric patients with focal seizures has 
been investigated in a large double-blind, placebo-controlled 
randomized trials in Europe and India.18 The authors 
recruited 207 (aged 6–17 years) patients who were taking 
one to two AEDs for focal seizures with or without second-
ary   generalization. Dose adjustments were made during a 
titration phase, to a target dose of 8 mg/kg/day (maximum 
500 mg/day). Responder rate was assessed during the 
12-week maintenance phase, and 50% of the zonisamide 
group had achieved a $50% reduction in partial seizure 
frequency, compared to 31% in the placebo group. The 
median decrease in seizure frequency from baseline was 
50% for zonisamide, compared to 24.5% for placebo, a 
difference that reached statistical significance. The authors 
concluded that adjunctive zonisamide treatment was shown 
to be effective and well tolerated in pediatric patients with 
partial epilepsy. There were three open-label studies involved 
mixed cohorts of both children and young adults.19–21 Cop-
pola et al20 reported seizure freedom in 10.9% of their 
sample, and a responder rate in 37.8%, at a mean dose of 
5.7 mg/kg/day as an add-on therapy in refractory partial 
epilepsy. Kluger et al19 assessed the use of zonisamide in 
24 patients with partial epilepsy. Responder rates were 58.3% 
at 8 weeks and 41.7% at 18 months. Guerrini et al’s21 exten-
sion study reported seizure freedom in 16% and a responder 
rate in 56.3% at dose of 8 mg/kg/day as an add-on therapy 
in refractory epilepsy. Another study looking at the use of 
zonisamide as an adjunctive therapy in pediatric populations 
reported a median decrease in seizure frequency of 1.3% per 
week, which approached statistical significance (P=0.056). 
Responder rate was not reported in this study.22
Furthermore, a retrospective case-notes review of pediat-
ric patients treated with adjunctive zonisamide found a low 
responder rate of 23.5% whereas the incidence of adverse 
effects was lower than other studies.23 Two retrospective stud-
ies were undertaken in patients with intractable epilepsy.24,25 
In the first study, 35 children (age: 8 months to 22 years; 
mean: 9 years) showed good to excellent seizure control 
(50%–100% reduction) in 42.8% of the all treated patients. 
Adverse effects were not associated with a higher mean dose. 
In the second retrospective study, 48.5% of 163 patients 
experienced a reduction in seizure frequency of more than Pediatric Health, Medicine and Therapeutics 2014:5 submit your manuscript | www.dovepress.com
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50% after ZNS adjunctive therapy, with 25 patients (15.3%) 
being seizure-free.
Zonisamide as monotherapy
There have been multiple retrospective chart-review studies 
suggesting the potential efficacy and safety of zonisamide 
as monotherapy in refractory partial seizures in adults and 
across the lifespan.26–28 Overall, the evidence to support the 
use of zonisamide in pediatric populations, particularly as 
monotherapy, is still limited. The available studies are sum-
marized in Table 1.
Three open-label studies considered the use of zonis-
amide as monotherapy in children.29–31 In these studies, 
seizure freedom ranged from 57% to 79% of patients; 
no significant differences in seizure-freedom rates were 
found between low- or high-dose zonisamide. Another 
open-label trial, including both pediatric and young adult 
population (aged 1–22 years), reported a lower rate of 
seizure freedom (29.8%) whereas a total of 101 patients 
(77.1%) achieved a 50% or greater decrease in seizure 
frequency (ie, responders).32
An additional two open-label studies evaluated the 
efficacy of zonisamide in children with epilepsy, but did 
not report separated results for patients on monotherapy 
or polytherapy.33,34
The large variability among the rate of seizure-free 
patients between the different trials can be explained by 
different factors, including their open-label nature and, 
mostly, the recruitment of adult patients in some studies.
In summary, the available literature suggests that zonis-
amide can be useful as monotherapy in pediatric patients 
who had received no previous treatment and in newly 
diagnosed partial epilepsy. However, further evaluation is 
needed with respect to efficacy, safety, and effectiveness 
in this population.
Safety and tolerability data
The pharmacokinetic profile of zonisamide has a number 
of advantages. First, the long half-life allows once-daily 
dosing, improves patient compliance, and suggests a low 
impact of missed doses on seizure control. However, it has 
to be acknowledged that the long half-life may represent a 
limitation when a rapid onset of action is required. In general, 
the majority of the reviewed trials suggest that zonisamide is 
an effective and well tolerated treatment option for pediatric 
patients with focal epilepsy. The occurrence of side effects 
in the different trials ranged from 26% to 81.4%.18–20 Side 
effects were usually mild in severity and resolved shortly after 
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discontinuation of the drug. The most frequently reported 
side effects included decreased appetite, decreased weight, 
somnolence, nausea/vomiting, and diarrhea; additionally, 
both psychiatric (eg, psychosis and suicidal ideation) or 
cognitive adverse effects were reported, and the high-dose 
group was significantly worse than that in the low-dose group, 
but that is in line with other new-generation AEDs.29,35 In 
many studies, patients experienced side effects during the 
escalation phase, of which the majority resolved during the 
maintenance of the medication.30
Teratogenic effects of zonisamide were not clearly defined 
from these studies even if the present data do not indicate that 
the risk of teratogenicity is greater than that of other conven-
tional AEDs.36 However, such risk cannot be neglected even 
at therapeutic dosages or concentrations of ZNS, especially 
in patients receiving polytherapy. In addition, postmarketing 
studies conducted in Japan revealed that pediatric patients 
on zonisamide have an increased risk for oligohydrosis 
and hyperthermia. Therefore, it is advisable that patients 
would be monitored closely for signs of decreased sweating 
and increased body temperature, especially in warm or hot 
weather.37
Discussion
Zonisamide (3-sulfamoylmethyl-1, 2-benzisoxazole) is an 
AED with a broad spectrum of mechanistic action that has 
demonstrated good efficacy in controlling seizures as an 
add-on therapy in adult and pediatric epilepsy.25,38–40 Despite 
some methodological drawbacks, our review of available 
literature supports the view that adjunctive zonisamide 
therapy is effective and well tolerated in pediatric patients 
with refractory partial epilepsy, and could therefore prove to 
be a useful new treatment option for this patient population. 
The evidence in support of the use of zonisamide in pediat-
ric populations, as monotherapy, is still limited, indicating 
the need for further investigation in randomized, controlled 
trials. In the available clinical trials, the titration schedule 
of the drug varied but, in general, the recommended dosage 
escalation starts at 1 mg/kg/day and increases at weekly 
intervals in increments of 1 mg/kg to the target dose of 6–8 
mg/kg/day up to a maximum dose of 300–500 mg/day in two 
daily doses. Of note, Sackellares et al showed that a slower 
(or 2-weekly) titration of zonisamide was associated with 
fewer adverse effects.41
The tolerability profile of zonisamide was high in the large 
majority of the studies, both in add-on and   monotherapy. 
From the review of the literature (Table 1), the risk of 
significant side effects is higher in patients in polytherapy. 
Notably, there are very limited data from clinical studies in 
patients with a body weight of less than 20 kg. Therefore, 
children aged 6 years and above and with a body weight less 
than 20 kg should be treated with caution.
In conclusion, zonisamide, as adjunctive therapy, and 
potentially as monotherapy, is successful in treating pedi-
atric patients with refractory partial seizures because of its 
structural and mechanistic profile, safety, tolerability, and 
wide spectrum of antiseizure activity. The challenge for 
new more-efficacious, more-specific, and better-tolerated 
drugs is also continuing. However, the ultimate goal should 
be to not only render the patients seizure-free, but also to 
allow for improvement of quality of life of individuals and 
to reduce the costs of medical care.
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